【摘要】 目的观察依达拉奉治疗高龄缺血性脑卒中的疗效观察及对血清D-二聚体和纤维蛋白原的影响。方法选取2015年12月—2017年1月霍邱县第二人民医院收治的77例高龄缺血性脑卒中患者为研究对象,按照随机数字表法分为观察组(n=35)和对照组(n=42),对照组患者给予常规基础对症治疗,观察组患者在对照组基础上给予注射依达拉奉,观察比较两组患者治疗疗效、治疗前和治疗后1个月和3个月神经功能缺损程度(NIHSS)和日常生活活动能力(ADL)评分及治疗前后血清D-二聚体和纤维蛋白原水平,并记录两组患者治疗期间不良反应发生率。结果治疗后观察组患者治疗有效率为97.14%,显著高于对照组78.57%(χ~2=4.299,P<0.05),治疗后1个月和3个月两组患者NIHSS评分较治疗前显著降低(t=9.503、12.384,7.242、9.949,P<0.05),而BI评分较治疗前显著升高(t=7.470、21.791,5.257、20.503,P<0.05),且观察组患者在治疗后1个月和3个月NIHSS评分显著低于对照组(t=3.476、5.441,P<0.05),而BI评分显著高于对照组(t=3.330、2.906,P<0.05),两组患者治疗后D-二聚体和纤维蛋白原水平较治疗前显著降低(t=8.538、9.343,5.530、5.016,P<0.05),且与对照组比较,观察组患者D-二聚体和纤维蛋白原水平显著降低(t=4.118,6.223,P<0.05),治疗期间两者患者均未出现严重不良严重反应。结论依达拉奉能够治疗高龄缺血性脑卒中临床症状,其机制可能与减少患血栓形成有关,通过降低血清D-二聚体和纤维蛋白原水平,减少患者术后神经功能损伤。更多还原

【Abstract】 Objective To observe the curative effect of edaravone in treatment of senile cerebral arterial thrombosis and effect on the serum D-two polymer and fibrinogen. Methods 77 cases of senile patients with cerebral arterial thrombosis admitted and treated in our hospital from December 2015 to January 2017 were selected and randomly divided into two groups, the control group with 42 cases used the routine basic systematic therapy, while the observation group used the injection of edaravone on the basis of the control group, and the NIHSS and ADL score and serum D-two polymer and fibrinogen of the two groups were observed and compared before treatment and in 1 month and 3 months after treatment, and the incidence rate of adverse reactions during the treatment of the two groups was recorded. Results After treatment, the treatment effective rate in the observation group was obviously higher than that in the control group(97.14% vs 78.57%)(χ~2=4.299, P<0.05). and the NIHSS scores in 1 month and 3 months of the two groups obviously decreased compared with those before treatment(t=9.503, 12.384, 7.242, 9.949, P<0.05), and the BI score obviously increased compared with that before treatment(t =7.470, 21.791, 5.257, 20.503, P <0.05), and the NIHSS score in 1 month and 3 months after treatment in the observation group was obviously lower than those in the control group(t =3.476, 5.441, P<0.05), and the BI score was obviously higher than that in the control group(t=3.330, 2.906, P<0.05),after treatment, the D-two polymer and fibrinogen level after treatment of the two groups obviously decreased(t=8.538,9.343, 5.530, 5.016, P <0.05), and the D-two polymer and fibrinogen level obviously decreased in the observation group(t=4.118, 6.223, P<0.05), during the treatment, there were no obvious serious adverse reaction during the treatment. Conclusion The edaravone can treat the clinical symptoms of senile cerebral arterial thrombosis, and the mechanism can be related to the reduction of thrombosis, and it can reduce the postoperative nerve function injuries by reducing the serum D-two polymer and fibrinogen level.更多还原